Dear Sir,

I have additional commentary to the letter which appeared in Molecular Genetics and Metabolism [@bb0005]. The authors of the letter comment a study for assessment of the current state of newborn screening (NBS) in the region of south-eastern Europe [@bb0010] previously published in your journal [@bb0010]. The authors correctly deny that PKU newborn screening was not introduced in Macedonia [@bb0005]. However, in Macedonia a selective newborn screening for inborn errors of metabolism, including PKU has been first implemented in 2012. As a matter of fact, newborn screenings for PKU and congenital adrenal hyperplasia (CAH) started in May 2002 and lasted until December 2004 year, with a total of 27,926 screened patients. No affected children were found. ELISA was used, with quality external control from the Dutch RIVM -- diagnostic laboratory for infection diseases and perinatal screening. Unfortunately, the authorities ceased to finance those screenings. In addition, the first CH and PKU screening in Macedonia, a result of noble endeavor by Dr. Nikola Stojanovski [@bb0015], started in the 1978 for PKU and in late 80s for both PKU and CH in the town and county of Veles Macedonia, while the laboratory analysis was performed in Zagreb, Croatia. Both screening lasted for a decade, discovering several patients with PKU and CH.

In conclusion, sustaining uninterrupted NS in Macedonia emerges as a main problem. NS must be a continuous activity. It is fortunate that NS for HT was not interrupted since 2002.
